Tislelizumab is a PD-1 inhibitor immunotherapy drug, belonging to monoclonal antibodies. It activates the human immune system to kill tumor cells by blocking the PD-1/PD-L1 pathway on the surface of tumor cells. It is mainly used for the treatment of advanced solid tumors and hematological tumors.
1、 Indications and mechanisms of action
Indications:
Currently approved in China for second-line or combination therapy of malignant tumors such as non-small cell lung cancer, urothelial carcinoma, Hodgkin lymphoma, and liver cancer. Clinical studies also explore its applications in fields such as esophageal cancer and gastric cancer.
Mechanism of action:
By specifically binding to PD-1 receptors, blocking the pathway of tumor cells using PD-L1 to evade immune surveillance, restoring T cell anti-tumor activity, and inhibiting tumor growth and metastasis.
2、 Precautions for use
Before medication, it is necessary to evaluate:
Potential beneficiaries need to be screened through pathological diagnosis and biomarker testing (such as PD-L1 expression levels). Patients with autoimmune diseases, a history of organ transplantation, or severe infections should use it with caution.
Common side effects:
Immune related adverse reactions: such as thyroid dysfunction, pneumonia, colitis, hepatitis, etc;
General reactions: fatigue, rash, itching, decreased appetite, etc.
3、 Medication guidance and monitoring
Administration method:
Usually administered intravenously, the dosage and duration need to be adjusted according to the tumor type and patient condition, and strict adherence to medical advice is required.
Monitoring during treatment:
Regularly review blood routine, liver and kidney function, thyroid function, etc;
Seek medical attention immediately when symptoms such as difficulty breathing, severe diarrhea, and persistent fever occur.
4、 Special populations and taboos
Pregnant women and lactation period:
May pose a risk to the fetus or infant and should be avoided.
contraindication:
It is contraindicated for those who are allergic to drug ingredients or have uncontrolled active autoimmune diseases.
Attention: Trastuzumab is a prescription drug that needs to be evaluated by a specialist oncologist before use. Close follow-up is required during the treatment process and dosage adjustment or discontinuation is not allowed. If serious adverse reactions occur, seek medical attention promptly and contact the attending physician to adjust the plan.
